Fred Saad

Summary

Country: Canada

Publications

  1. ncbi A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    J Natl Cancer Inst 94:1458-68. 2002
  2. ncbi Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Urol Oncol 24:4-12. 2006
  3. ncbi Research in genitourinary oncology: the Canadian Uro-Oncology Group multidisciplinary model
    Fred Saad
    , University of Montreal, Canada
    BJU Int 102:7-8. 2008
  4. ncbi Natural history and treatment of bone complications in prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Eur Urol 49:429-40. 2006
  5. ncbi The role of bisphosphonates in the management of prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Curr Oncol Rep 8:221-7. 2006
  6. ncbi The role of bisphosphonates in hormone-refractory prostate cancer
    Fred Saad
    Division of Urology, Department of Surgery, Centre Hospitalier de l Universite de Montreal, Montreal, PQ H2L 4M1 Quebec, 1560 Rue Sherbrooke East, Canada
    World J Urol 23:14-8. 2005
  7. ncbi The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel
    Fred Saad
    Universite de Montreal, Quebec, Canada
    Clin Genitourin Cancer 4:257-62. 2006
  8. ncbi Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    BJU Int 96:964-9. 2005
  9. ncbi Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Eur Urol 46:731-39; discussion 739-40. 2004
  10. ncbi Bone-directed treatments for prostate cancer
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hospital Notre Dame, Department of Surgery Urology, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    Hematol Oncol Clin North Am 20:947-63. 2006

Detail Information

Publications104 found, 100 shown here

  1. ncbi A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    J Natl Cancer Inst 94:1458-68. 2002
    ..We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with bone metastases...
  2. ncbi Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Urol Oncol 24:4-12. 2006
    ..According to this algorithm, zoledronic acid should be considered for the prevention of skeletal morbidity in patients with prostate cancer throughout their treatment continuum...
  3. ncbi Research in genitourinary oncology: the Canadian Uro-Oncology Group multidisciplinary model
    Fred Saad
    , University of Montreal, Canada
    BJU Int 102:7-8. 2008
  4. ncbi Natural history and treatment of bone complications in prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Eur Urol 49:429-40. 2006
    ....
  5. ncbi The role of bisphosphonates in the management of prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Curr Oncol Rep 8:221-7. 2006
    ..Therefore, bisphosphonates, particularly zoledronic acid, may provide important benefits for preserving bone health during the course of prostate cancer progression...
  6. ncbi The role of bisphosphonates in hormone-refractory prostate cancer
    Fred Saad
    Division of Urology, Department of Surgery, Centre Hospitalier de l Universite de Montreal, Montreal, PQ H2L 4M1 Quebec, 1560 Rue Sherbrooke East, Canada
    World J Urol 23:14-8. 2005
    ..Therefore, initiation of zoledronic acid therapy should be considered to prevent skeletal morbidity and improve the quality of life of these patients...
  7. ncbi The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel
    Fred Saad
    Universite de Montreal, Quebec, Canada
    Clin Genitourin Cancer 4:257-62. 2006
    ..However, further study of the use of bisphosphonates across the clinical spectrum of prostate cancer is needed...
  8. ncbi Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    BJU Int 96:964-9. 2005
    ..In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long-term use...
  9. ncbi Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    Eur Urol 46:731-39; discussion 739-40. 2004
    ....
  10. ncbi Bone-directed treatments for prostate cancer
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hospital Notre Dame, Department of Surgery Urology, 1560 Rue Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    Hematol Oncol Clin North Am 20:947-63. 2006
    ....
  11. ncbi Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    J Natl Cancer Inst 96:879-82. 2004
    ..Long-term treatment with 4 mg of zoledronic acid is safe and provides sustained clinical benefits for men with metastatic hormone-refractory prostate cancer...
  12. ncbi Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier, University of Montreal, Montreal, Quebec, Canada
    Clin Prostate Cancer 1:145-52. 2002
    ..Zoledronic acid is the first and only bisphosphonate shown to reduce skeletal morbidity, including fractures, in patients with advanced prostate cancer and bone metastases...
  13. ncbi Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, QC, Canada
    Nat Clin Pract Urol 4:S3-13. 2007
    ..The early diagnosis and treatment of bone loss and bone metastases with bisphosphonates are critical for the maintenance of skeletal wellness and prevention of bone complications in patients with prostate cancer...
  14. ncbi A population based assessment of perioperative mortality after cystectomy for bladder cancer
    Hendrik Isbarn
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    J Urol 182:70-7. 2009
    ..Contemporary estimates range from 0.7% to 5.6%. We tested several predictors of perioperative mortality and devised a model for individual perioperative mortality prediction...
  15. ncbi Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada
    J Urol 181:601-7; discussion 607-8. 2009
    ..Identifying patients at risk for early recurrence may improve prognosis as early institution of adjuvant therapy may reduce the risk of progression...
  16. ncbi Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis
    Jean Simon Diallo
    Centre de recherche du Centre Hospitalier de l Université de Montréal CR CHUM, Institut du Cancer de Montreal, Quebec, Canada
    BJU Int 101:1302-9. 2008
    ....
  17. ncbi Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer
    Benjamin Péant
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada H2L 4M1
    Mol Cancer Res 5:87-94. 2007
    ..To our knowledge, this is the first report of an IkappaB kinase family member whose expression is modulated by androgen and deregulated in androgen receptor-negative cells...
  18. ncbi The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients
    Naeem Bhojani
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Int J Radiat Oncol Biol Phys 76:342-8. 2010
    ..We tested this hypothesis in a large French Canadian population-based cohort of prostate cancer patients...
  19. ncbi Accuracy of life tables in predicting overall survival in patients after radical prostatectomy
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 102:33-8. 2008
    ....
  20. ncbi Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases
    Laurent Lessard
    Centre de recherche du Centre Hospitalier de l Universite de Montreal, Institut du Cancer de Montreal, and the Department of Surgery Urology, CHUM, University of Montreal, 1560 rue Sherbrooke Est, Montreal, Quebec, Canada
    Clin Cancer Res 12:5741-5. 2006
    ..Because nuclear factor-kappaB (NF-kappaB) is a candidate marker of prostate cancer progression, we tested the association between nuclear localization of NF-kappaB in radical prostatectomy specimens and the presence of LNI...
  21. ncbi Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer
    Ismael H Koumakpayi
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
    BJU Int 100:303-9. 2007
    ....
  22. ncbi High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer
    Claudio Jeldres
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Eur Urol 54:97-105. 2008
    ..We examined the effect of annual and cumulative provider volume on the rate of use of secondary therapies after definitive external-beam radiotherapy (EBRT) for localized prostate cancer...
  23. ncbi NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells
    Laurent Lessard
    Universite de Montreal, Centre de recherche du CHUM et Institut du cancer de Montréal, 1560 Sherbrooke East, Montreal, QC, Canada, H2L 4M1
    Cell Signal 19:1093-100. 2007
    ..These results point to a novel mechanism by which androgens regulate NF-kappaB and provide a rationale for further studies into the biological significance of non-canonical NF-kappaB signalling in prostate cancer...
  24. ncbi A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    J Clin Oncol 25:3576-81. 2007
    ..To circumvent this problem, we developed a nomogram predicting 10-year LE for patients treated with either radical prostatectomy (RP) or external-beam radiation therapy (EBRT) and compared it with an existing tool...
  25. ncbi Prostate volume and adverse prostate cancer features: fact not artifact
    Alberto Briganti
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Canada
    Eur J Cancer 43:2669-77. 2007
    ..We investigated the association between prostate size and prostate cancer grade and stage in a large (n=3412) single center radical prostatectomy cohort, which was unexposed to any form of hormonal manipulation...
  26. ncbi Radical versus partial nephrectomy: effect on overall and noncancer mortality
    Laurent Zini
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Cancer 115:1465-71. 2009
    ..Relative to radical nephrectomy (RN), partial nephrectomy (PN) performed for renal cell carcinoma (RCC) may protect from non-cancer-related deaths. The authors tested this hypothesis in a cohort of PN and RN patients...
  27. ncbi Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men
    Andrea Gallina
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Int J Cancer 123:647-52. 2008
    ..In conclusion, our data suggest that prostate biopsy might predispose to higher mortality rate. The certainty of this association remains to be proven...
  28. ncbi Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    BJU Int 100:1254-8. 2007
    ....
  29. ncbi Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men
    Claudio Jeldres
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Eur Urol 54:107-16. 2008
    ..We examined the rate of 10-yr survival in septa- and octogenarians treated for prostate cancer with either attempted curative external beam radiotherapy (EBRT) or radical prostatectomy (RP)...
  30. ncbi Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells
    Cécile Le Page
    Centre de recherche du Centre Hospitalier de l Université de Montréal CR CHUM, 1560 rue Sherbrooke Est, Montreal, Quebec, Canada
    Prostate 65:306-15. 2005
    ....
  31. ncbi External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy
    Shahrokh F Shariat
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    J Clin Oncol 26:1526-31. 2008
    ..However, this model was never externally validated. We tested the accuracy of this nomogram in an independent, external cohort...
  32. ncbi Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer
    Jochen Walz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Int J Radiat Oncol Biol Phys 69:88-94. 2007
    ..To test the accuracy of life tables (LTs) in predicting survival in men treated with radiotherapy for localized prostate cancer...
  33. ncbi Comparative study of inguinal hernia repair rates after radical prostatectomy or external beam radiotherapy
    Giovanni Lughezzani
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Int J Radiat Oncol Biol Phys 78:1307-13. 2010
    ....
  34. ncbi NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model
    Jean Simon Diallo
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Quebec, Canada
    Clin Cancer Res 13:7044-52. 2007
    ..To assess the expression of proapoptotic NOXA and PUMA in prostate tissues and delineate their association with prostate cancer (PCa) recurrence...
  35. ncbi Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer
    Philippe O Gannon
    Centre de recherche du Centre hospitalier de l Université de Montréal CRCHUM and Institut du cancer de Montréal, Montreal, Quebec, Canada
    PLoS ONE 5:e12107. 2010
    ..Arginase 2 (ARG2) expression by PCa cells leads to a reduced activation of tumor-specific T cells. Our hypothesis was that androgens could regulate the expression of ARG2 by PCa cells...
  36. ncbi Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines
    Benjamin Péant
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Quebec, Canada
    Prostate 69:706-18. 2009
    ..Previous studies, in murine embryonic fibroblasts, have shown that Ikappa-B kinase-epsilon (IKKepsilon/IKKi)-deficiency results in the reduction of lipopolysaccharide-mediated expression of IL-6...
  37. ncbi The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone
    Fred Saad
    University of Montreal Hospital Centre, Montreal, PQ, Canada
    BJU Int 102:551-5. 2008
    ....
  38. ncbi Validation of 1997 Partin Tables' lymph node invasion predictions in men treated with radical prostatectomy in Montreal Quebec
    Pierre I Karakiewicz
    Department of Surgery (Urology, , , , Canada
    Can J Urol 12:2588-92. 2005
    ..740). However, accuracy was lower than reported in internal (0.818), and external (0.837) academic, validation cohorts. Accuracy of LNI predictions was appreciably higher, when continuously coded PSA was used...
  39. ncbi [NFkappaB : a new marker kappable of predicting prostate cancer outcome]
    Laurent Lessard
    , 1560 Sherbrooke Est, , QC, Canada, H2L 4M1
    Bull Cancer 93:891-9. 2006
    ..The addition of NFkappaB and other molecular markers to current clinical markers will facilitate the identification of high risk patients and guide clinicians in the choice of an appropriate therapeutic approach...
  40. ncbi Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia
    Claudio Jeldres
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
    J Urol 182:626-32. 2009
    ....
  41. ncbi Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort
    Umberto Capitanio
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Urology 73:1323-7. 2009
    ..To examine the distribution of total prostate-specific antigen (tPSA) and percentage of free/total PSA (%f/tPSA) values in patients undergoing prostate cancer screening in Canada...
  42. ncbi A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma
    Laurent Zini
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
    Clin Cancer Res 15:1013-8. 2009
    ..We attempted to develop a simpler prediction rule with at least equal accuracy in predicting CSM after surgical removal of PPSCC...
  43. ncbi An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines
    Jean-Simon Diallo
    , Montreal, Quebec, Canada
    Prostate 66:1245-56. 2006
    ..01). CONCLUSION: We conclude that resistance to IP6 can be linked to a ligand-independent AR function...
  44. ncbi Expression and nuclear localization of ErbB3 in prostate cancer
    Ismael Herve Koumakpayi
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Quebec, Canada
    Clin Cancer Res 12:2730-7. 2006
    ..The aim of this study was to analyze the expression and localization of ErbB3 in prostate tissues and prostate cancer cell lines...
  45. ncbi Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer
    Fred Saad
    Centre Hospitalier de i Université de Montréal, Hopital Notre Dame, Montreal, Quebec, Canada
    Urology 76:1175-81. 2010
    ..ZOL has shown significant reductions in SREs and pain compared with placebo in patients with bone metastases from advanced prostate cancer in a randomized placebo-controlled trial...
  46. ncbi Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Canada
    Expert Rev Anticancer Ther 10:1991-2002. 2010
    ..Emerging therapies are being investigated for their ability to maintain bone health. The findings presented herein highlight the importance of bone-targeted therapies for patients with bone metastases from prostate cancer...
  47. ncbi Therapeutic approach to hormone-refractory prostate cancer
    Fred Saad
    University of Montreal Health Center, CHUM, Montreal, Quebec, Canada
    Can J Urol 13:52-6. 2006
    ..Introducing these effective therapies earlier in high risk patients is also under investigation to further improve outcomes...
  48. ncbi Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer
    Vincent Fradet
    Département de chirurgie urologie, Centre Hospitalier de l Université de Montreal Montréal, Montreal, Quebec, Canada
    Clin Cancer Res 10:8460-4. 2004
    ....
  49. ncbi Prostate cancer nomograms are superior to neural networks
    Pierre I Karakiewicz
    Department of Urology, University of Montreal, Montreal, Quebec, Canada
    Can J Urol 13:18-25. 2006
    ..CONCLUSION: In the field of PCa detection, nomograms appear to outweigh the benefits of neural networks. However, the neural network methodology represents a valid alternative, which should not be underestimated...
  50. ncbi Preventing bone complications in prostate cancer
    Mohamed Bishr
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
    Curr Opin Support Palliat Care 6:299-303. 2012
    ..These events significantly impair the patient's quality of life and place a significant burden on health-care resources...
  51. ncbi Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Montreal, QC, Canada
    Urol Oncol 30:369-78. 2012
    ....
  52. ncbi Preservation of bone health in prostate cancer
    Jean Baptiste Lattouf
    Urologic Oncology Division, Centre Hospitalier de l Universite de Montreal, Canada
    Curr Opin Support Palliat Care 1:192-7. 2007
    ..Given the magnitude of bone-related morbidity in advanced prostate cancer, physicians need to be aware of preventive and therapeutic measures, and to be proactive in implementing them...
  53. ncbi Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers
    Fred Saad
    Centre Hospitalier de l Université de Montréal and CRCHUM, 1560 Sherbrooke East, Montreal, Quebec H2L 4M1, Canada
    Anticancer Agents Med Chem 12:129-36. 2012
    ..This review examines the rationale and emerging evidence supporting the anticancer activity of bisphosphonates, especially ZOL, against prostate and other genitourinary cancers...
  54. ncbi Identification of spermatozoa in archived testicular cancer specimens: implications for bench side sperm retrieval at orchiectomy
    Guila Delouya
    Division of Urology, Department of Radiation Oncology, Centre Hospitalier de l Universite de Montreal, and Department of Surgery, McGill University, Montreal, Quebec, Canada
    Urology 75:1436-40. 2010
    ..To evaluate the patterns of spermatogenesis in the normal testicular parenchyma of primary testicular cancers and estimate the feasibility of sperm retrieval at the time of radical orchiectomy...
  55. ncbi Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Clin Genitourin Cancer 5:390-6. 2007
    ..We conducted several retrospective exploratory analyses to determine whether zoledronic acid has continuing efficacy during long-term treatment...
  56. ncbi SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer
    Fred Saad
    University of Montreal, CHU Montreal, 1560 Sherbrooke East, Montreal, Quebec, Canada
    Cancer Treat Rev 36:177-84. 2010
    ..Data arising from ongoing and future clinical trials will confirm whether SRC inhibitors provide clinical benefits for patients with advanced disease...
  57. ncbi Maintaining bone health in prostate cancer throughout the disease continuum
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Quebec, Canada
    Semin Oncol 37:S30-7. 2010
    ..This review will examine the breadth of evidence supporting a role for ZOL and emerging therapies in managing patients with PC throughout the disease continuum...
  58. ncbi Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening
    Georg Hutterer
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, 1058, rue St Denis, Montreal, Que, Canada
    Eur J Cancer 43:1180-7. 2007
    ..Body mass index (BMI) may alter serum prostate specific antigen (PSA) and percent free PSA (%fPSA) and may mask the risk of prostate cancer. We investigated the relationship between BMI and PSA or %fPSA...
  59. ncbi Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
    Philippe O Gannon
    Research Centre of the Centre Hospitalier de l Université de Montréal CRCHUM, Notre Dame Hospital and Institut du cancer de Montréal 1560 Sherbrooke East, Montreal, Quebec, Canada
    J Immunol Methods 348:9-17. 2009
    ..Our goal was to study the hormonal regulation of immune cell infiltration in prostate cancer patients treated by androgen deprivation therapy (ADT) using an optimized computer-assistance quantification approach...
  60. ncbi Validation of prostate cancer index and SF-12 short forms
    Thierry Lebeau
    Department of Urology, University of Montreal, Montreal, Quebec, Canada
    Can J Urol 12:2873-9. 2005
    ..The short forms have the potential for decreasing respondent burden and infrastructure-related requirements, which may in turn promote HRQOL assessment after radical prostatectomy...
  61. ncbi Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors
    Umberto Capitanio
    University of Montreal Health Center, Quebec, Canada
    Urology 74:373-7. 2009
    ..8% for postchemotherapy RPLND) are applicable to institutions at large...
  62. ncbi Bone complications of androgen deprivation therapy: screening, prevention, and treatment
    Jean Baptiste Lattouf
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    Curr Opin Urol 20:247-52. 2010
    ..We herein discuss available strategies to avoid bone loss in this patient population...
  63. ncbi New research findings on zoledronic acid: survival, pain, and anti-tumour effects
    Fred Saad
    Centre Hospitalier de i Université de Montréal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, Quebec, Canada PQ H2L 4M1
    Cancer Treat Rev 34:183-92. 2008
    ..To summarize the current evidence for clinical, anti-tumour, and survival benefits from zoledronic acid in patients with genitourinary cancers...
  64. ncbi Role of bisphosphonates in prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Quebec, H2L 4M1, Montreal, Canada
    Eur Urol 45:26-34. 2004
    ..Although the success of current therapeutic options has extended the survival of patients with prostate cancer, they often develop skeletal morbidity from disease and treatment-related effects that undermine skeletal integrity...
  65. ncbi Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL
    Andrea Gallina
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Eur Urol 52:1374-80. 2007
    ..To test this hypothesis, we examined 5193 consecutive patients subjected to radical prostatectomy (RP) for localized prostate cancer (PCa)...
  66. ncbi Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer
    Fred Saad
    Department of Surgery, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec H2L 4M1, Canada
    Clin Prostate Cancer 4:31-7. 2005
    ..Therefore, zoledronic acid provides long-term continuing clinical benefit for men with prostate cancer and bone metastases and represents a new therapeutic option for this population...
  67. ncbi Bone-marker levels in patients with prostate cancer: potential correlations with outcomes
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    Curr Opin Support Palliat Care 4:127-34. 2010
    ..Although bone scans are a reliable means of assessing osteoblastic lesions, tools for monitoring early changes in bone health are lacking. Biochemical markers of bone turnover might fulfill this unmet need...
  68. ncbi Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Quebec, Canada
    Semin Oncol 37:S38-44. 2010
    ..Bone metastases place a heavy burden on patients with RCC or bladder cancer, and early, continuous treatment with ZOL may provide anticancer benefits in addition to important patient quality of life...
  69. ncbi Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid
    Fred Saad
    Department of Surgery/Urology, , , Quebec, Canada
    Semin Oncol 29:19-27. 2002
    ..The role of zoledronic acid in the treatment of patients with prostate cancer continues to evolve...
  70. ncbi Zoledronic acid: past, present and future roles in cancer treatment
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Department of Surgery Urologic Oncology, 1560 Rue Sherbrooke East, Montreal, PQ H2L 4M1 Quebec, Canada
    Future Oncol 1:149-59. 2005
    ..Due to its unique pharmacologic profile, zoledronic acid has activity in a variety of clinical settings at low doses and with infrequent intravenous dosing...
  71. ncbi Cancer treatment-induced bone loss in breast and prostate cancer
    Fred Saad
    Department of Surgery Urology, Centre Hospitalier de l Universite de Montreal, University of Montreal, Montreal, Quebec, Canada
    J Clin Oncol 26:5465-76. 2008
    ..Bone loss resulting from the treatment of breast and prostate cancer is an emerging problem. Bisphosphonates have a potential role in the prevention of this cancer treatment-induced bone loss (CTIBL)...
  72. ncbi Bone loss in prostate cancer: evaluation, treatment and prevention
    Fred Saad
    Department of Surgery/Urology, , , , Quebec, Canada
    Can J Urol 12:71-6; discussion 99-100. 2005
    ..Bisphosphonates may be beneficial in preventing bone loss and eventually reducing skeletal morbidity due to prostate cancer and ADT...
  73. ncbi Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease
    Fred Saad
    Department of Surgical Oncology, Centre Hospitalier de l Université de Montréal Hôpital Notre Dame, Montreal, Quebec, Canada
    Semin Oncol 34:S17-23. 2007
    ..Furthermore, normalization of NTX values correlated with extended survival...
  74. ncbi Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases
    Fred Saad
    University of Montreal, Montreal, Quebec, Canada
    BJU Int 101:1071-5. 2008
    ..Cumulative evidence supports RANKL inhibition as a therapeutic goal for the treatment and prevention of bone metastases from prostate cancer...
  75. ncbi Src as a therapeutic target in men with prostate cancer and bone metastases
    Fred Saad
    CHUM, University of Montreal, Montreal, Quebec, Canada
    BJU Int 103:434-40. 2009
    ..This review explores Src inhibition as a strategy for managing bone metastasis in prostate cancer, with a particular focus on targeting the critical osteoclastic response. Other emerging and novel approaches are also considered...
  76. ncbi Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature
    Fred Saad
    University of Montreal, CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
    Can J Urol 13:16-24. 2006
    ..Is there a known association between duration of wait time beyond the recommended standard and clinical outcome (i.e. recurrence free survival, overall survival)?..
  77. ncbi Digital rectal exam following prostatectomy: is it still necessary with the use of PSA?
    Jean Baptiste Lattouf
    Department of Urology, Centre Hospitalier de l Universite de Montreal, Universite de Montreal, Que, H2L 4M1, Montreal, Canada
    Eur Urol 43:333-6. 2003
    ..To establish the value of digital rectal exam with respect to PSA in the follow up of radical prostatectomy for prostate adenocarcinoma...
  78. ncbi The role of bisphosphonates in the management of bone metastases in prostate cancer
    Fred Saad
    Department of Urology, University of Montreal (CHUM, Montreal, Quebec, Canada
    Can J Urol 11:2376-82. 2004
    ..This article reviews the burden of skeletal complications in patients with prostate cancer, and the evidence for the use of bisphosphonates for the treatment of skeletal morbidity in this patient population...
  79. ncbi uPM3, a new molecular urine test for the detection of prostate cancer
    Yves Fradet
    , , , Canada
    Urology 64:311-5; discussion 315-6. 2004
    ..5 and 4.0 ng/mL, respectively. CONCLUSIONS: These results suggest that the uPM3 molecular urine test may be an important adjunct to current methods for the detection of early prostate cancer...
  80. ncbi Isolated solitary bony metastasis of a nonseminomatous germ cell tumor
    Abdulhadi Aldejmah
    Department of Surgery, Division of Urology, Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    Can J Urol 14:3458-60. 2007
    ..He was treated with a left orchiectomy and four cycles of chemotherapy containing bleomycin, etoposide, and cisplatin. He attained complete remission...
  81. ncbi Optimizing patient therapy: the role of bone markers?
    Fred Saad
    Universite de Montreal, CHUM Hopital Notre Dame, 1560 Sherbrook E, Montreal, Quebec H2L 4M1, Canada
    Cancer Treat Rev 32:3-6. 2006
    ..This review examines SREs and the burden they impose on patients, the relationship between SREs and bone turnover markers, and the potential role of bone markers in guiding treatment and improving patients' quality of life (QOL)...
  82. ncbi UPM3: review of a new molecular diagnostic urine test for prostate cancer
    Fred Saad
    , , , , Canada
    Can J Urol 12:40-3; discussion 99-100. 2005
    ..5 and 4 ng/ml, respectively). This test may become one of the first molecular diagnostic tools to aid in prostate cancer detection...
  83. ncbi Sunitinib relieves renal cell carcinoma spinal cord compression
    Quoc Dien Trinh
    Department of Urology, Division of Urologic Oncology University of Montreal Health Center, Montreal, Quebec, Canada
    Eur Urol 51:1741-3. 2007
    ..Moreover, it appears that the novel therapies for metastatic RCC may restore quality and quantity of life to many of those, whose disease previously appeared too advanced to treat...
  84. ncbi Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinoma
    Philippe O Gannon
    Centre de recherche du CHUM CRCHUM and Institut du cancer de Montréal, Montreal, QC, Canada
    Cancer Immunol Immunother 59:1411-6. 2010
    ..Altogether, these observations support the current understanding of carcinogenesis promoted by chronic inflammation...
  85. ncbi Presence of prostate cancer metastasis correlates with lower lymph node reactivity
    Philippe Olivier Gannon
    , , , Canada
    Prostate 66:1710-20. 2006
    ..005). CONCLUSIONS: Our results suggest that the development of prostate cancer LN metastasis is accompanied with smaller LN size and decreased LN reactivity suggesting the development of an immununosuppressive microenvironment...
  86. ncbi A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
    Michael A Carducci
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer 110:1959-66. 2007
    ..The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin-A receptor antagonist, in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  87. ncbi Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Robert E Coleman
    Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, England, UK
    J Clin Oncol 23:4925-35. 2005
    ..These trials provide an opportunity for investigating the correlation between bone metabolism and clinical outcome during bisphosphonate therapy...
  88. ncbi Bisphosphonates in prostate cancer: where are we and where should we go?
    Fred Saad
    J Natl Cancer Inst 95:1262-3. 2003
  89. ncbi Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 70:315-9. 2007
    ..Skeletal complications are a major cause of morbidity in men with hormone-refractory metastatic prostate cancer. These analyses were designed to identify the variables associated with a greater risk of skeletal complications...
  90. ncbi Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
    Venita Depuy
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Support Care Cancer 15:869-76. 2007
    ..We sought to quantify the longitudinal effects on patient-reported outcomes of skeletal-related events (SREs) and to ascertain the declines in health-related quality of life (HRQOL) and pain experienced by patients who experienced SREs...
  91. ncbi The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate
    Allan Lipton
    Milton S Hershey Medical Center, P O Box 850 H 46, Hershey, PA 17003, USA
    Cancer Invest 20:45-54. 2002
    ..In conclusion, Zol is the first bisphosphonate to demonstrate efficacy in both lytic and blastic disease. The unique properties of this novel agent should be further explored in future clinical trials...
  92. ncbi Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer
    Richard J Cook
    Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada
    Clin Cancer Res 12:3361-7. 2006
    ..In multivariate models, higher levels of serum BAP but not urinary N-telopeptide are associated with shorter overall survival...
  93. ncbi Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
    Fred Saad
    BJU Int 97:1351-2. 2006
  94. ncbi Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:2918-25. 2005
    ..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy...
  95. ncbi Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer
    Kim N Chi
    Prostate Centre at Vancouver General Hospital, BC Cancer Agency, Vancouver Centre and the Canadian Uro Oncology Group, Vancouver, British Columbia, Canada
    J Urol 180:565-70; discussion 570. 2008
    ..We assessed pathological outcomes as well as the feasibility of combined docetaxel and androgen deprivation therapy in men with prostate cancer before undergoing prostatectomy...
  96. ncbi Bone health in men with prostate cancer: diagnostic and therapeutic considerations
    Fred Saad
    University of Montreal Health Center, Montreal, Quebec Canada
    Can J Urol 12:9-15. 2005
    ..New generation bisphosphonates such as zoledronic acid can prevent bone loss for patients on ADT and can reduce skeletal morbidity for those with bone metastases...
  97. ncbi Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
    Janet E Brown
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England, United Kingdom
    J Natl Cancer Inst 97:59-69. 2005
    ..N-telopeptide levels were more consistent prognostic indicators than bone-specific alkaline phosphatase for all tumor types, reflecting the key role of osteolysis in the development of skeletal complications...
  98. ncbi Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
    Allan Lipton
    Department of Hematology Oncology, Milton S Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA
    Cancer 113:193-201. 2008
    ..For patients with bone metastases, high N-telopeptide of type I collagen (NTX) levels correlate with increased risks of skeletal-related events and death. However, the relation between NTX decreases and clinical benefits is unclear...
  99. ncbi The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion
    J Curtis Nickel
    Department of Urology, Queen's University, Kingston, Ontario, Canada
    Can J Urol 11:2186-93. 2004
    ..Although our perspective is clearly different than our US colleagues, it is likely that the guideline will influence the management of BPH in Canada...
  100. ncbi Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 179:1593-7. 2008
    ....
  101. ncbi Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center Durham, North Carolina, USA
    J Urol 171:1537-42. 2004
    ..However, the cost-effectiveness ratios for bisphosphonates are higher than commonly cited thresholds for conferring cost-effectiveness...